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Abstract: After the fall of communism, the healthcare systems of Central and Eastern European
countries underwent enormous transformation, resulting in departure from publicly financed health-
care. This had significant adverse effects on equity in healthcare, which are still evident. In this
paper, we analyzed the role of government and households in financing healthcare in eight countries
(EU-8): Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, and Slovenia. A desk research
method was applied to collect quantitative data on healthcare expenditures and qualitative data on
gaps in universal health coverage. A linear regression analysis was used to analyze a trend in health
expenditure over the years 2000–2018. Our results indicate that a high reliance on out-of-pocket pay-
ments persists in many EU-8 countries, and only a few countries have shown a significant downward
trend over time. The gaps in universal coverage in the EU-8 countries are due to explicit rationing (a
limited benefit package, patient cost sharing) and implicit mechanisms (wait times). There is need to
increase the role of public financing in CEE countries through budget prioritization, reducing patient
co-payments for medical products and medicines, and extending the benefit package for these goods,
as well as improving the quality of care.
Keywords: healthcare financing; universal health coverage; Central and Eastern European countries
1. Introduction
The economic and political transformation in postsocialist countries initiated after
1989 has gotten an impressive body of literature [1–6]. Transformation processes in Central
and Eastern European (CEE) countries are among the most significant events of the end
of the twentieth century [7]. An important component of transformation in postsocialist
countries was the change of the healthcare system. The reforms following the collapse
of communism, provoked by a sharp economic decline, resulted in departure from the
centralized and nationalized healthcare systems of the Semashko model [8–10]. The scope
of transformation was wide, starting from a shift in ownership (transforming public
entities into private ones and/or establishing private healthcare entities), through changes
in organization (disintegration of care and strengthening primary healthcare), and ending
up with changes in healthcare financing (introduction of social health insurance in most
CEE countries) [9–11].
It was expected that the shift towards an insurance-based system with market-oriented
features in CEE countries would ensure sufficient and more stable funds for healthcare
and improve efficiency (also through increasing patient responsibility for financing health-
care) [8–10]. The reforms were, however, seldom based on evidence, and they suffered
from institutional shortcomings, e.g., insufficient contribution rates or poor effectiveness
in collection of contributions [8,9,12]. To add to this, their implementation encountered
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difficult economic condition. Thus, the outcomes of the reforms were far from expected.
Patient out-of-pocket payments grew significantly, increasing inequality in healthcare sys-
tems [13]. Households were made responsible for financing healthcare though formal cost
sharing [14–16]. On top of this, informal patient payments, already present during the
communist era, became even more widespread during the transition period [17,18].
Currently, 30 years after the collapse of communism, CEE countries are still struggling
to ensure sufficient public resources for health and catch up with Western European
countries in ensuring universal health coverage, i.e., equal access to necessary healthcare
without financial hardship for patients [19]. The economic crisis of 2008 stood in the way,
strongly affecting many CEE countries and perpetuating differences between east and
west Europe [20]. The current crisis caused by the COVID-19 pandemic might similarly
have detrimental effects on healthcare systems. The future also holds challenges for the
countries of this region. Rapid population ageing due to particularly low fertility rates, in
addition to migration, will very likely deepen the fiscal imbalance in health budgets of the
CEE countries [21].
In this paper, we analyzed the role of the government and households in financing
healthcare in eight CEE countries: Czechia, Estonia, Hungary, Latvia, Lithuania, Poland,
Slovakia, and Slovenia. These countries were the first in the CEE region to join the Euro-
pean Union (EU) in 2004 (referred to as the EU-8). We have analyzed quantitative data
on healthcare expenditure since 2000, as well as qualitative data on the gaps in public
healthcare coverage in terms of population and services excluded from coverage, as well as
patient obligation to share the cost of publicly financed healthcare. This allowed us to see
what directions CEE countries are moving in, regarding government responsibility for fi-
nancing healthcare, and indicate the obstacles to achieving universal health coverage—one
of the health-related United Nations sustainable development goals.
The details on the methods applied in this study are presented in the next section.
This is followed by the results presented separately for quantitative and qualitative data
analysis. The last two sections include discussion of the results and conclusions drawn
from our research.
2. Materials and Methods
This study aimed to analyze the role of government and households in financing
healthcare in the EU-8 countries. All of the included countries share similar experiences
with the Siemasko healthcare system, and they all began a series of healthcare reforms in
the 1990s, although it should be noted that there have been differences across the countries,
e.g., in the extent of the undertaken reforms, their speed, and the economic and social
environment of the health systems. At present, all these countries, with the exemption
of Latvia, rely on social health insurance to collect resources for healthcare, though only
Czechia and Slovakia have a competitive insurance model [22–29]. The countries differ
significantly in demographic, social, and economic characteristics, with Latvia having
the smallest population, the highest old-age dependency ratio, and the lowest GDP per
capita. Slovenia and Czechia are the most developed countries with the highest GDP
per capita and the highest Human Development Index score, as well as the longest life
expectancy. The World Bank’s governance effectiveness index is rather low in all of the
analyzed countries, particularly in Hungary and Poland. Across the countries, there is
close to universal support for the state being responsible for ensuring access to healthcare.
For details, see Table 1.
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Table 1. Characteristics of the included countries.
Czechia Estonia Hungary Latvia Lithuania Poland Slovakia Slovenia
Population (thousands) (2018) 10,610 1319 9778 1934 2809 37,977 5443 2067
Population density (persons per
km2) (2018) 137.7 30.4 107.1 30.4 44.7 123.6 111.8 102.9
Life expectancy at birth, total
(years) (2018) 79.1 78.5 76.2 75.1 76.0 77.7 77.4 81.5
Old-age dependency ratio (2018) 29.6 30.6 28.5 31.4 30.1 25.3 22.5 29.6
GDP per capita, PPP (current
international $) (2018) 41,036 36,222 32,086 30,736 36,011 31,851 32,538 38,841
Human Development Index † (2018) 0.898 0.889 0.850 0.863 0.876 0.877 0.858 0.912
Government Effectiveness Index ‡ (2018) 0.92 1.19 0.49 1.04 1.07 0.66 0.71 1.13
Healthcare for the sick: percentage
claiming it should be the government’s
responsibility (2016) §
95.8 n.d. 98.0 98.0 96.0 n.d. 98.2 98.9
† The Human Development Index (HDI) is a composite index that captures human development in three dimensions: health (measured by
life expectancy at birth), education (measured by mean of years of schooling for adults aged 25 years and more, and expected years of
schooling for children of school entering age), and income (measured by gross national income per capita) [30]. ‡ Government Effectiveness
Index is the World Bank’s aggregate governance indicator that reflects perceptions of the quality of public services, the quality of the
civil service and the degree of its independence from political pressures, the quality of policy formulation and implementation, and the
credibility of the government’s commitment to such policies. Estimates range from approximately −2.5 (weak) to 2.5 (strong) governance
performance [31]. § Results of a cross-sectional survey on the nationally representative sample of all individuals aged over 15 years. Survey
question: “On the whole, do you think it should or should not be the government’s responsibility to provide healthcare for the sick.
Answers “definitely should” and “probably should” are included [32].
To meet the aim of the study, a desk research method has been applied. A narrative
literature review of databases and publications by the Organization for Economic Co-
operation and Development (OECD), the World Health Organization (WHO), and the EU,
was conducted between May 2020 and January 2021 to identify and collect quantitative
and qualitative data on healthcare expenditure and healthcare coverage by government
schemes in the EU-8 countries.
The quantitative component of our study relied on data on healthcare expenditure from
the National Health Accounts available in OECD and WHO databases [33,34]. We selected
five health expenditure indicators, which enabled a comprehensive analysis of healthcare
financing with the focus on the respective roles of government and households, namely:
• Current health expenditure as % of GDP—this presents total spending on healthcare
goods and services (excluding investment spending) by all types of financing arrange-
ments (compulsory schemes, household out-of-pocket payments, voluntary health
insurance, non-governmental organizations etc.) in relation to country GDP. Source of
data: OECD Health Statistics (accessed on 20 July 2020) [33].
• Domestic general government health expenditure as % of general government
expenditure—this compares the scale of current public health expenditure (by all
financing agents holding public domestic funds) relative to the total scale of govern-
ment expenditure. Thus, it indicates the government’s priority to spend on health
out of its own domestic public resources. Source of data: World Health Organization
Global Health Expenditure Database (accessed on 10 January 2021) [34].
• Government/compulsory scheme expenditure as % of current health
expenditure—this presents the share of government (central and regional/local) and
compulsory financing schemes (e.g., compulsory health insurance) in the total current
expenditure. This mostly includes spending by government and social health insur-
ance, though compulsory private health insurance is also included if present. Source
of data: OECD Health Statistics (accessed on 20 July 2020) [33].
• Household out-of-pocket health expenditure as % of current health expenditure—out-
of-pocket expenditures are payments borne directly by patients when using healthcare.
They include direct payments for privately purchased healthcare (without involve-
ment of third-party payers, e.g., an insurer) and patient cost sharing for goods and
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services covered by third-party payers. This also includes estimations of informal
payments to healthcare providers when such data are available. Source of data: OECD
Health Statistics (accessed on 20 July 2020) [33].
• Household out-of-pocket expenditure as % of health expenditure for given types
of services—this gives more detailed information on household contributions to
financing healthcare, and indicates the areas where public coverage is limited. Source
of data: OECD Health Statistics (accessed on 20 July 2020) [33].
To present the changes in health expenditure over the years, in our analysis we have
considered a time span of 19 years (from 2000 until 2018). In order to explore whether a
trend is evident in health expenditure data over the years, we applied a linear least squares
regression analysis (using MS Excel 2016, and R version 4.0.3), where time was used as an
explanatory variable. The analysis was performed for each country as well for the whole
group, including countries’ variables in the model.
In order to have a better picture of household involvement in financing healthcare, we
also examined more in-depth information on healthcare coverage by government schemes
and compulsory insurance schemes. We considered three dimensions of coverage:
• Population coverage—population entitlement to a benefit package, financed from
government or compulsory insurance schemes;
• Service coverage—the range of goods and services included in a benefit package. We
focused on healthcare benefits (primary care, outpatient and inpatient specialist care, den-
tal care, medical products, medicines), excluding sickness benefits or maternity benefits
(even if in some countries they are financed though the obligatory health insurance fund).
When analyzing service coverage, we also looked at the quality of services in a benefit
package. Quality might be considered the fourth dimension of healthcare coverage, as
gaps in this aspect might also lead to out-of-pocket patient payments.
• Cost coverage—patient cost-sharing obligations for healthcare in a benefit package. This
might include a) flat-rate payments (co-payments) per good or service; b) percentage
co-payments (sometimes referred to as co-insurance) when a patient pays a share of the
price; c) deductibles, which require users to pay up to a fixed amount first, before the
state/insurer will cover any costs. Patients might be also asked to cover any cost over
the amount of money reimbursed by the insurer/state if the price of service or good
exceeds the reimbursement amount (balance billing/extra billing/reference pricing).
Data for this qualitative analysis have largely been obtained from the country and
cross-country reports found on the websites of the OECD, WHO, and EU, which allow us
to ensure a relatively high degree of comparability of data between countries. These key
reports have been selected:
• The Health Systems in Transition (HiT) country profiles by the European Observatory
on Health Systems and Policies;
• The State of Health in the EU country profiles by the OECD and the European Obser-
vatory on Health Systems and Policies;
• Universal Health Coverage: Financial Protection Country Reviews by the WHO
Regional Office for Europe;
• The Health at a Glance report series by the OECD and the EU.
We cross-checked data from these various sources in order to assure their validity.
They are mostly of a qualitative nature, though, if available, quantitative data on healthcare
coverage were also collected. We mostly present the current situation in the countries, yet
we also attempt to outline the changes in policies related to coverage over the years.
3. Results
In this section, we first analyzed the data on healthcare expenditure in the EU-8 countries.
Then, we present the results of the qualitative data analysis of the dimensions of universal
health coverage, i.e., population entitlement universality, coverage of services in the benefit
package, and quality and access to these services, as well as patient cost-sharing obligations.
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3.1. Healthcare Expenditure
Table 2 presents data on the four health expenditure indicators for each country,
including their value at the beginning and at the end of the analyzed period, the minimum
and maximum annual growth rate (percentage change over previous year) during this
period, and the estimated simple linear regression model to examine the trend in health
expenditure data over the years. The definitions of the indicators are included in the
methods section, while the Supplementary Materials (Figures S1–S32 and Table S1) include
a full dataset on health expenditure and a graphical presentation of linear regression results.
Table 2. Healthcare expenditure in the EU-8 countries (Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, and









Current health expenditure as % of GDP
Czechia 5.72 7.65 −5.4 (2015) 14.7 (2009) y = 0.098x + 5.790, R2 = 0.758, p < 0.01
Estonia 5.16 6.66 −8.0 (2011) 14.6 (2008) y = 0.111x + 4.553, R2 = 0.784, p < 0.01
Hungary 6.78 6.70 −7.3 (2007) 14.0 (2003) y = −0.027x + 7.542, R2 = 0.129, p = 0.131
Latvia 5.45 6.21 −9.3 (2011) 13.4 (2004) y = 0.011x + 5.661, R2 = 0.046, p = 0.376
Lithuania 6.19 6.57 −10.9 (2004) 17.0 (2009) y = 0.037x + 5.891, R2 = 0.233, p < 0.05
Poland 5.30 6.33 −3.2 (2018) 8.5 (2008) y = 0.050x + 5.643, R2 = 0.644, p < 0.01
Slovakia 5.30 6.69 −8.2 (2014) 18.7 (2004) y = 0.090x + 5.828, R2 = 0.395, p < 0.01
Slovenia 7.80 8.33 −4.0 (2007) 8.7 (2009) y = 0.043x + 7.787, R2 = 0.439, p < 0.01
Domestic general government health expenditure as % of general government expenditure
Czechia 12.38 15.54 −4.6% (2003) 15.8 (2013) y = 0.195x + 11.508, R2 = 0.824, p < 0.01
Estonia 10.80 12.54 −6.6 (2002) 5.6 (2003) y = 0.119x + 10.191, R2 = 0.851, p < 0.01
Hungary 9.86 9.92 −8.1 (2007) 19.7 (2003) y = −0.045x + 10.523, R2 = 0.154, p = 0.097
Latvia 7.43 9.60 −9.2 (2008) 23.7 (2004) y = 0.037x + 8.468, R2 = 0.083, p = 0.232
Lithuania 10.57 12.70 −25.9 (2004) 11.8 (2002) y = 0.067x + 10.947, R2 = 0.141, p = 0.113
Poland 8.59 10.83 −5.2 (2010) 8.1 (2008) y = 0.132x + 8.561, R2 = 0.872, p < 0.01
Slovakia 8.89 12.65 −7.6 (2015) 17.0 (2001) y = 0.129x + 11.112, R2 = 0.336, p < 0.01
Slovenia 11.72 13.80 −18.5 (2013) 15.7 (2014) y = 0.053x + 11.774, R2 = 0.157, p = 0.093
Government/compulsory scheme expenditure as % of current health expenditure
Czechia 89.80 83.03 −3.1 (2008) 1.4 (2009) y = –0.472x + 89.835, R2 = 0.801, p < 0.01
Estonia 76.97 73.67 −2.7 (2017) 1.8 (2001) y = −0.122x + 77.231, R2 = 0.312, p < 0.05
Hungary 69.65 69.45 −2.7 (2007) 2.0 (2002) y = −0.129x + 69.903, R2 = 0.224, p < 0.05
Latvia 50.75 59.88 −5.0 (2012) 12.7 (2004) y = 0.499x + 52.309, R2 = 0.393, p < 0.01
Lithuania 68.51 67.05 −11.7 (2004) 5.2 (2007) y = −0.272x + 71.969, R2 = 0.280, p < 0.05
Poland 68.88 71.49 −2.0 (2004) 3.1 (2001) y = 0.059x + 69.543, R2 = 0.085, p = 0.226
Slovakia 89.16 80.13 −11.6 (2004) 8.7 (2008) y = −0.425x + 82.591, R2 = 0.135, p = 0.121
Slovenia 72.90 72.93 −2.2 (2007) 2.8 (2008) y = −0.043x + 73.042, R2 = 0.083, p = 0.231
Out-of-pocket health expenditure as % of current health expenditure
Czechia 10.20 14.19 −11.2 (2013) 18.4 (2008) y = 0.300x + 10.242, R2 = 0.629, p < 0.01
Estonia 20.37 24.56 −8.5 (2008) 9.4 (2017) y = 0.186x + 20.127, R2 = 0.516, p < 0.01
Hungary 27.33 26.89 −4.5 (2002) 5.4 (2001) y = 0.053x + 26.637, R2 = 0.068, p = 0.280
Latvia 47.66 39.18 −16.3 (2004) 10.3 (2012) y = −0.404x + 44.834, R2 = 0.258, p < 0.05
Lithuania 27.15 31.64 −10.8 (2007) 36.1 (2004) y = 0.291x + 26.873, R2 = 0.338, p < 0.01
Poland 31.12 20.42 −10.5% (2018) 6.8 (2004) y = −0.457x + 29.897, R2 = 0.867, p < 0.01
Slovakia 10.84 18.91 −23.2 (2008) 71.2 (2004) y = 0.335x + 16.230, R2 = 0.134, p = 0.123
Slovenia * 12.47 11.93 −7.3 (2008) 11.1 (2007) y = −0.033x + 12.905, R2 = 0.133, p = 0.165
* Due to the lack of data, the value of the indicator, out-of-pocket health expenditure as % of current health expenditure, for Slovenia is
from 2003, and the regression analysis covers data for 2003–2018.
Int. J. Environ. Res. Public Health 2021, 18, 1382 6 of 26
The presented data show great diversity in healthcare expenditure indicators across
the countries. The annual growth rates also indicate that there were falls and rises in their
levels during the analyzed period.
In 2018, current healthcare expenditure as percentage of GDP ranged from 6.2% in
Latvia to 8.3% in Slovenia. Since 2000, the expenditure has increased in all countries but
Hungary. Data suggest that Hungary has been marked with a small decrease of current
health expenditure as share of GDP, though this was from a relatively high level, i.e., 6.8%
in 2000. The results of linear trend regression analysis show a statistically significant linear
trend for all countries but Latvia and Hungary, with the highest average annual increase in
Estonia, where the rate of current health expenditure as percentage of GDP has increased
on average by 0.11 annually. In some of the countries, the sharpest rise in the value of the
indicator occurred during the economic crisis of 2008, which can be attributed to a drop in
the GDP level.
Domestic general government health expenditure as percentage of general govern-
ment expenditure in 2018 ranged from 9.6% in Latvia to 15.5% in Czechia. Data indicate
that since 2000, all governments have increased the priority given to healthcare when
making decisions regarding public expenditure, with the exception of Hungary. Yet, a
statistically significant upward trend was only observed in Czechia, Estonia, Poland, and
Slovakia. The highest increase in the share of public expenditure devoted to health between
2000 and 2018 was in Slovakia (by 3.8 p.p.), albeit from the low level of 9%.
The data on the contribution of public spending and household out-of-pocket payments
in health expenditure showed great diversity across the countries. The differences observed
in 2000 have persisted until recent years as countries have moved in different directions.
Among the eight countries, Czechia and Slovakia are characterized by the highest share of
public spending in current health expenditure (83% and 80%, respectively, in 2018). Public
involvement in financing healthcare in Czechia and Slovakia was already high in 2000
(nearly 90%) and these two countries have been marked with the highest decrease in the
public share (by 7 and 9 p.p. in Czechia and Slovakia, respectively) and an increase in the
out-of-pocket share in financing healthcare by 4 and 8 p.p. respectively. In Czechia, the
decreasing trend for public spending and the increasing trend for out-of-pocket payments
were statistically significant, while in Slovakia no stable trends could be seen. At the
opposite end is Latvia, with the lowest share of public financing and the highest share of
out-of-pocket payments (60% and 39%, respectively, in 2018). The situation in Latvia has
improved throughout the years, with a statistically significant increasing trend of the rate
of the public share in healthcare expenditure, on average by 0.5 per year, and the highest
overall growth among all the countries, i.e., by 9 p.p. between 2000 and 2018.
In all other countries (Lithuania, Hungary, Poland, Slovenia, Estonia) the public share
in healthcare spending ranged from 67% to 74% (2018) and there were rather small changes
between 2000 and 2018 (+/–3 pp), though a significant decreasing trend in Hungary,
Lithuania, and Estonia might raise concerns. Poland, on the other hand, has managed to
reduce the contribution of households in financing healthcare by nearly 11 p.p. between
2000 and 2018, and the results of linear trend regression analysis confirm a decreasing
trend over the years, with an average decrease of 0.5 per year. The observed improvement
in Poland can be attributed to the growing importance of other financing sources, i.e.,
voluntary health insurance. Yet, the role of private insurance was rather negligible in the
analyzed countries, and only in Slovenia did its share of healthcare spending reach 15%
(data not presented).
The results of multiple regression analyses, where data for all countries were included
(Table 3), indicated a small but statistically significant upward trend in current health
expenditure as percentage of GDP and government health expenditure as percentage of
general government spending. On the other hand, the public share in healthcare spending
showed a downward trend, while no significant trend was found in the share of out-of-
pocket payments. Moreover, the results confirm statistically significant differences in the
four indicators of health expenditure across the EU-8 countries.
Int. J. Environ. Res. Public Health 2021, 18, 1382 7 of 26
Table 3. The results of the multiple regression analysis.
Current Health









% of Current Health
Expenditure
Out-of-Pocket Health
Expenditure as % of
Current Health
Expenditure
Coeff. (S.E.) Coeff. (S.E.) Coeff. (S.E.) Coeff. (S.E.)
Time 0.052 *** (0.007) 0.086 *** (0.012) −0.113 * (0.048) 0.037 (0.046)
Czechia 1.105 *** (0.145) 2.080 *** (0.254) 9.109 *** (1.043) −8.743 *** (0.973)
Estonia ref. ref. ref. ref.
Hungary 1.607 *** (0.145) −1.307 *** (0.254) −7.394 *** (1.043) 5.185 *** (0.963)
Latvia 0.109 (0.145) −2.541 *** (0.254) −18.716 *** (1.043) 18.812 *** (0.963)
Lithuania 0.599 *** (0.145) 0.234 (0.254) −6.7574 *** (1.043) 7.798 *** (0.963)
Poland 0.472 ** (0.145) −1.497 ***(0.254) −5.879 *** (1.043) 3.349 *** (0.963)
Slovakia 1.064 *** (0.145) 1.024 *** (0.254) 2.329 * (1.043) −2.399 * (0.963)
Slovenia 2.547 *** (0.145) 0.926 *** (0.254) −3.396 ** (1.043) −9.457 *** (0.963)
Constant 5.149 *** (0.122) 10.521 *** (0.213) 77.141 *** (0.878) 21.608 *** (0.825)
Observations 152 152 152 149
F test F(8, 143) = 66.82 *** F(8, 143) = 71.23 *** F(8, 143) = 108.1 *** F(8, 140) = 161.5 ***
R-squared 0.789 0.799 0.858 0.897
Adj. R-squared 0.777 0.788 0.850 0.891
*** p < 0.001, ** p < 0.01, * p < 0.05.
Figure 1 shows that there is great diversity in the shares of out-of-pocket payments
in financing different types of healthcare. Households mostly contribute to financing
medical products (therapeutic appliances) (up to 89% in Latvia), dental care (up to 84%
in Lithuania), and medicines (up to 63% in Poland). Nevertheless, the share of household
out-of-pocket payments in financing outpatient specialized services is also high in some
countries, e.g., 50% in Latvia and 43% in Hungary.
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insurance system, which is currently present in all countries but Latvia. Thus, the right to 
publicly financed healthcare is mainly conditional on the participation in the insurance 
scheme. Nevertheless, selected groups (usually those eligible for any kind of pension/so-
cial assistance, children, registered unemployed), which account for a significant share of 
population (>50% in Czechia, Estonia, Lithuania, Slovakia), either are insured by the state 
or are covered without contribution paid on their behalf. 
The review of available evidence showed that the majority of analyzed countries 
have achieved universal (or near universal) population coverage for their respective ben-
efit packages. Three countries (Czechia, Latvia, Slovenia) reported that 100% of the popu-
lation is covered by the national health system. In another countries, the gaps in popula-
tion coverage (up 9% in Poland) concern the citizens living and working abroad or are 
due to shortcomings of the insurance system, which is not flexible and transparent enough 
to permanently cover all individuals eligible for the coverage, e.g., those with nonstand-
ard employment (part-time work, temporary employment, work based on employment 
relationship other than employment contracts, informal employment). More details are 
presented in Table 4.
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3.2. Healthcare Coverage
3.2.1. Population Coverage
The results of our review indicate that the healthcare systems in the EU-8 countries
are intended to serve the whole population, and the health insurance law requires all
citizens and legally employed temporary residents to participate in the obligatory health
insurance system, which is currently present in all countries but Latvia. Thus, the right
to publicly financed healthcare is mainly conditional on the participation in the insurance
scheme. Nevertheless, selected groups (usually those eligible for any kind of pension/social
assistance, children, registered unemployed), which account for a significant share of
population (>50% in Czechia, Estonia, Lithuania, Slovakia), either are insured by the state
or are covered without contribution paid on their behalf.
The review of available evidence showed that the majority of analyzed countries have
achieved universal (or near universal) population coverage for their respective benefit
packages. Three countries (Czechia, Latvia, Slovenia) reported that 100% of the population
is covered by the national health system. In another countries, the gaps in population
coverage (up 9% in Poland) concern the citizens living and working abroad or are due
to shortcomings of the insurance system, which is not flexible and transparent enough
to permanently cover all individuals eligible for the coverage, e.g., those with nonstan-
dard employment (part-time work, temporary employment, work based on employment
relationship other than employment contracts, informal employment). More details are
presented in Table 4.
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Table 4. Population coverage in the EU-8.
Country Basis for Entitlement % of Population Covered Noncovered Groups
Contribution Paid by the
Government or Coverage without
Contribution Paid on Behalf of
Noncontributors
Additional Information
Czechia Participation ininsurance scheme [35]. 100% [36,37]. n/a
State-paid contribution for 17
population groups (58% of
population), including children and
students up to the age of 26, disabled
people, pensioners, the unemployed,
and informal caregivers [22,38].
The contribution for state-insured groups is
fixed and substantially lower than an
average contribution from salary [22].






State-paid contribution for 24% of
the insured (e.g., pensioners, people
on parental leave, caregivers).
No contribution is paid for ~26% of
the covered population (e.g.,
children, students up to the age of 24,
the unemployed) [23,39,40].
The government started paying
contributions for pensioners in 2018 in order
to increase the financial stability of the
system [23,39].
Health coverage has been gradually
extended, e.g., registered jobseekers were







or without a fixed
address [24].
State-paid contribution for selected
groups, mainly pensioners, minors,
students [42].
The government pays for a significant share
of the health insurance fund exceeding
revenues from wage-based health insurance
contributions [43].
In practice, noncovered individuals also
receive necessary healthcare services [24,42].
Latvia Residence [25]. 100% [25,36,44]. n/a n/a
Between 2018 and 2019, a mandatory health
insurance system was in place. The full
benefit package was available for
individuals paying the insurance
contribution and to those in one of 21
population groups covered by the state (e.g.,
children, pensioners). Others were granted
access to a minimum benefit package
financed by the state (emergency care,
primary care, maternity care, psychiatric
care, treatment of infectious diseases, and
reimbursement of pharmaceuticals) [25,45].
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Table 4. Cont.
Country Basis for Entitlement % of Population Covered Noncovered Groups
Contribution Paid by the
Government or Coverage without
Contribution Paid on Behalf of
Noncontributors
Additional Information
Lithuania Participation ininsurance scheme [46]. 98% [26,36].
Individuals not in regular
employment, people working
abroad [26].
State-paid contribution for 55–60% of
the population, including pensioners,
social assistance beneficiaries,
children under 18, students,
registered unemployed, disabled
individuals, patients suffering from
certain communicable
diseases [46,47].
Emergency healthcare is provided free of
charge to all permanent residents











State-paid contribution for farmers of
small farms, registered jobseekers,
recipients of income support, clergy,
children, and students if they are not
co-insured family members. No
contribution is paid for co-insured
family members (22% of the insured
population) [48,49].
For pregnant women and children under 18,
the right to publicly financed healthcare can
be granted irrespective of their insurance
status.
Since 2017, all people, regardless of
insurance status, have had free access to
primary care.
Individuals not insured but eligible for
public coverage can be insured retroactively





94–96% [28,36,50]. Mostly individuals workingabroad [28,50].
State-paid contribution for the
economically inactive (dependent
family members, students and
pensioners) (in total >50% of
population) [28,50].
The insurance rate of the state-paid
contribution has been fluctuating over the
years, and now it is lower than the rate for
the economically active, contributing to a













prisoners, and war veterans [52].
In addition to public coverage, about 95% of
the population purchase voluntary health
insurance to cover obligatory patient
payments [29].
Note: data from OECD Report [36] on the share of population covered refer to population coverage for a core set of services (which generally include consultations with physicians, tests/examinations and
hospital care) under public programs and through primary private health insurance. Yet, the scale of private insurance as a primary source of coverage is negligible in the analyzed countries. n/a—not applicable.
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3.2.2. Service Coverage and Quality of Care
In the EU-8 countries, the benefit package is most often defined by positive lists (see
Table 5), though in some countries negative lists, which explicitly exclude certain benefits
from the coverage, are also present, i.e., Czechia, Hungary, and Latvia. In two countries
(Lithuania, Slovenia), there are no comprehensive explicit lists of services included or
excluded from the public coverage. In Czechia, although the list is defined, services not
included on the list might be still provided free of charge to patients depending on their
medical needs. The lists of services are revised on a rather ad hoc basis while the list of
medicines is most often periodically updated (e.g., every two months in Poland). Deci-
sions regarding benefits packages for medicines are also informed by Health Technology
Assessment (HTA) and are more transparent, following EU regulations (Council Directive
89/105/EEC of 21 December 1988) [53]. The economic crisis of 2008 proved to have some
impact on service coverage; e.g., in Estonia, Latvia, and Czechia, the benefit package has
been restricted.
In the majority of the countries, service coverage is rather comprehensive, and includes
prescribed spa treatment or even over-the-counter medicines if prescribed by a physician
(Czechia), along with the basic healthcare services, such as primary healthcare, specialized
inpatient and outpatient care, disease prevention, rehabilitation, prescription medicines,
medical products, and emergency care. The services most often excluded from the benefit
package are dental care for adults (with some services covered), employer-requested health
examinations, medical certificates, and cosmetic surgery. Also, the scope of available
medicines and medical products is considered limited in some countries. Nevertheless,
rather small differences across the eight countries in the coverage of essential health services
were confirmed by the data on the universal health coverage (UHC) service coverage index,
which ranged from 71 in Latvia to 79 in Slovenia.
Although a relatively broad range of available services, patients might be faced with
limits on the number of services to which they are entitled, e.g., infertility treatments in
Hungary, rehabilitation and dental care in Poland. Access to care might be also restricted
due to volume or quota limits imposed by public payers on healthcare providers to match
the available public resources. Moreover, most of the countries do not specify any waiting
time guarantees. This leads to long waiting times, which is one of the reasons for unmet
needs and high out-of-pocket payments as a result of using care in the private sector.
The shortages of medical professionals and their uneven distribution might undermine
timely and equal access to healthcare in the EU-8 countries. In 2018, on average across EU
countries, there were 3.8 practicing doctors and 8.2 practicing nurses per 1000 population.
Among the analyzed countries, the rates were similar or higher only for Czechia (for
physicians and nurses), Estonia (for physicians), and Slovenia (for nurses).
The Health Consumer Index scores confirmed that quality of care in the countries
at hand remains a challenge, as none of the analyzed countries reached the level of more
than 750 points, which is a threshold for “green countries”, meaning those where patients
positively assess the quality of healthcare services. The index scores were particularly low
for Hungary, Poland and Latvia.
3.3. Patient Cost Sharing for Goods and Services in a Benefit Package
Obligatory patient cost sharing for outpatient services (GPs and/or specialists) and
inpatient hospital services included in the benefit package is present in three countries (Es-
tonia, Latvia, and Slovenia) (see Table 6). In these countries, the system of patient payments
for services had already been introduced in the 1990s, and in later years only modified. In
three countries, i.e., Czechia, Hungary, and Slovakia, cost sharing for healthcare services
was implemented after 2000, but then withdrawn due to public and political opposition.
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Table 5. Service coverage and quality of care in the EU-8 countries.
Country Benefit Package Example ofIncluded/Excluded Services Quality and Access to Healthcare Changes in the Benefit Package Additional Information
†,‡
Czechia
Positive list of services,
medicines, medical
products.
Negative list of services
explicitly excluded [37].
Included: in vitro fertilization, spa
treatments, over-the-counter
medicines (if prescribed), dental
care (least expensive options)
[22,37].




some medical aids, e.g.,
prescription glasses [22,37].
There might be limitations on
volume of services provided by
specific providers [37].
No problems with waiting times
[33].
Regional disparities in the
distribution of physicians [22]
4.0 doctors and 8.1 nurses per 1000
population [54].
During the economic crisis of
2008, dental benefits were
restricted [55].
Periodic (several times a year)
amendments of the medicine
list [56].
Services not included on the
positive list may still be
reimbursed, depending on the
needs of individual patients.
Also, there are exceptional cases
in which items on the negative
list may be reimbursed [37].





Positive lists of services,
medicines, medical
products [39].
Included: dental care for children,





Maximum waiting time guarantees,




3.0 doctors and 6.3 nurses per 1000
population [54].
Between 2002 and 2017, cash
benefit instead of in-kind dental
care benefits for adults).
Coverage of dental care for
adults restricted during the
economic crisis of 2008, restored
in 2017 [23,39].
Benefit package updated at least
once a year [23].





Negative list of services.
Positive and negative list
of medicines [42,57].
Included: spa treatment, infertility
treatments (limits on number of
benefits) [42].
Excluded: cosmetic surgery,
medical certificates, abortion or
sterilization without medical
indication, selected dental services
for adults [42].
Performance volume limit set for
each provider [24].
Long waiting times [42].
Shortages and uneven distribution
of medical professionals [24].
3.4 doctors and 6.6 nurses per 1000
population [54].
Ad hoc revision of medicine lists
[56].
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Table 5. Cont.
Country Benefit Package Example ofIncluded/Excluded Services Quality and Access to Healthcare Changes in the Benefit Package Additional Information
†,‡
Latvia
Positive list of medicines
and certain services.
Negative lists of services
explicitly excluded [25].
Included: dental care for children
[39]




hearing aids for adults,
psychotherapy, spa treatment,
abortion (if no medical or social
indications) [44,45].
Volume limits on contracted
services. Lack of waiting time





3.3 doctors and 4.4 nurses per 1000
population [54].
Reduction of benefit package
after the economic crisis in
2008 [45].
Periodic (every 3 months)
amendments of the medicine
list [56].
The scope of the benefit package
is considered relatively limited,
particularly for outpatient care,
medicines, medical
devices [25,45].
UHC service coverage index:
71 [58].
HCI: 605 points (30th
place) [57].
Lithuania
No explicitly defined list
of services.
Positive list of medicines
and medical products
[26,46].
Included: dental care for children
and individuals on income
support, in vitro fertilization (since
2017) [26,46,47].






Long waiting times [46].
Uneven geographical distribution
of medical professionals; shortages
of nurses [26].
4.6 doctors and 7.8 nurses per 1000
population [54].
Periodic revision of medicine list
since 2019 [26].
Coverage of pharmaceuticals and
medical products is
limited [26,46].
UHC service coverage index:
73 [58].
HCI: 622 points (28th
place) [57].
Poland
Positive lists for services,
medicines, medical
products [48,49].
Included: spa treatment, basic
dental services for adults with
more services for children [48,49].




counter medicines, in vitro
fertilization [48,49].
Limits on the volume of services
contracted.
Lack of waiting time guarantees
and long waiting times [27,49].
Sever shortages of medical
professionals and their uneven
distribution [27].
2.4 doctors and 5.1 nurses per 1000
population [54].
Periodic (every 2 months)
amendments of the medicine
list [56].
Ad hoc revision of the service list.
In vitro fertilization was covered
between 2013 and 2016, and then
was excluded due to political
reasons [48].
Lists of guaranteed services in
primary care, outpatient
specialist care, and hospital care
are fairly comprehensive. In the
case of some services
(rehabilitation, dental care,
medical products), limits on the
number of services to be
provided per person [27,49].
UHC service coverage index:
75 [58].
HCI: 585 points (32nd place) [57].
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Table 5. Cont.
Country Benefit Package Example ofIncluded/Excluded Services Quality and Access to Healthcare Changes in the Benefit Package Additional Information
†,‡
Slovakia
Positive list of services,
medical products and
medicines [50].
Included: spa treatment, some
dental services for adults [50].
Excluded: most dental care,
patient-requested anesthesia,
paternity tests, specialist visits
without referral, treatment caused
by substance abuse, cosmetic
plastic surgery, abortion upon
request of the patient,
sterilization [50,59].
Budget ceilings resulting in
waiting times for specialists [59].
Shortages of healthcare
professionals and their uneven
distribution [28].
3.5 doctors and 5.7 nurses per 1000
population [54].
Periodic (every 3 months)
amendments of the medicine
list [56].
The benefit package is broadly
defined. Some attempts to define
a narrower benefit package
(2002–2004) were
unsuccessful [59].
UHC service coverage index:
77 [58].
HCI: 722 points (17th
place) [57].
Slovenia
The list of covered
services only broadly
defined [52,60]. Positive
and negative list of
medicines [52].








Maximum waiting times, but not
always met for specialist care
[29,52].
Low number of physicians [29].
3.2 doctors and 10.1 nurses per
1000 population [54].
Although the majority of services
are covered, they might be
subject to percentage
co-payments (up to 90%) (see:
section on patient cost sharing).
UHC service coverage index:
79 [58].
HCI: 678 points (21st
place) [57].
† UHC—universal health coverage. UHC service coverage index is Sustainable Development Goal (SDG) indicator. It is defined as a coverage index for essential health services based on tracer interventions that
include reproductive, maternal, newborn and child health, infectious diseases, noncommunicable diseases, and service capacity and access. The index ranges from 0 to 100 [58]. ‡ HCI—Health Consumer Index.
HCI presents the assessment of the performance of national healthcare systems in 35 countries (on the 1000-point scale) using 46 indicators, from the areas such as patient rights and information, access to care,
treatment outcomes, range and reach of services, prevention and use of pharmaceuticals [57].
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Cost Sharing for Outpatient
Medicines











The difference between the price
and the reimbursement
amount [22].
Payments for medical products
and dental care beyond the
standard package (cost above the
reimbursement amounts)
[22,37,61].
A yearly payment limit of 5000
CZK (~€200) for payments for
medicines. Lower limits apply to
children up to 18 years of age and
seniors (both since 2018), as well
as disabled people (since 2020).
Selected vulnerable groups are
fully exempt [22,37].
Between 2008 and 2015, there were
co-payments for services: 30 CZK
(€1.20) per doctor visit, 60 CZK (€2.40)
(100 CZK since 2011) per hospital day.
There was also cost sharing for
medicines in the form of a flat fee of 30
CZK (€1.20) for each prescribed
pharmaceutical (since 2012 per
prescription). Due to the unpopularity
of user fees, some local governments
(controlled by the opposition) had
reimbursed patients for the user
charges before fees were fully
abolished in 2015 [37,61].
Estonia
Co-payments for outpatient
specialist care (€5 per visit),
inpatient care (€2.50 per
day), and primary care




prescription (€2.50), a percentage
co-payment (0%, 25%, 50%), and
any additional costs above the
reference price [39,40].
Dental care for adults: percentage
co-payment of 50% with a benefit
cap of €40 per year (15% and €85
respectively for some
vulnerable groups)
For medical products: percentage
co-payments of 10% or 50% [39].
A cap on payments for hospital
stays (€25 per hospitalization).
Caps on payments for outpatient
medicines, i.e., if the total
spending on prescription
medications in a year reaches
€100, then the insurance fund
starts to reimburse 50% of the
cost above €100. This
reimbursement rate increases up
to 90% for out-of-pocket
spending above €300. Over the
years, these spending thresholds
have been decreasing [23,39,40].




Cost sharing for services was first
introduced in 1995. The system was
modified by the 2002 Health Insurance
Act, which set the maximum
co-payment levels. In 2013, the
maximum fee level was increased.
Cost sharing for dental care was
introduced in 2017, when in-kind
dental care was included in the benefit
package [39].








Cost Sharing for Outpatient
Medicines







Percentage co-payments (up to
75%) or a fixed co-payment. The
co-payment rate depends on the
therapeutic value of the
medicine, the severity and status
of the disease (with lower rates
for more severe or longer lasting
disease) [24,56,62].
Different flat and percentage
co-payment rates for medical
products.
Cost sharing for dental care
(adults) [42].
A monthly personal budget of up
to 12,000 HUF (€40) to cover
co-payments for prescribed
medicines for specific vulnerable
groups (the disabled, low-income
individuals).
Limited exemption scheme for
some vulnerable population
groups [24].
Between 2007 and 2008, patients paid a
flat co-payment of 300 HUF (approx.
€1) per outpatient visit and a per diem
for inpatient care (for max. 20
visits/days of hospitalization per year).
The fees were withdrawn as a
consequence of a nation-wide
referendum [14,63].
Latvia
Co-payment of €1.42 per
primary care visit, €4.28 per
specialist visit, and €10 per
day of
hospitalization [44,45].
A flat fee of €0.71 per
prescription or percentage
co-payments of 25% or 50%, and
any additional costs above the
reference price [44,45].
For medical products: a flat fee of
€0.71 per prescription or
percentage co-payments of 25%
or 50%, and any additional costs
above the reference price [44,45].
Caps on the total annual
payments for inpatient and
outpatient services (€569 per
person per year) and on
payments for inpatient stay (€356
per hospitalization) (but no cap
on payments for medicines and
medical products). Exceptions
from payments for some
population groups, including
children, pregnant women,
people suffering from certain
diseases, and since 2009, for
low-income individuals [44,45].
Flat co-payments were first
implemented in 1995, and in the late
90s, a percentage co-payment (up to
25% of service costs) was applied to
selected services. Due to the
complexity of the system, in 2004, it
was simplified with only flat
co-payments remaining [64].
In 2009, due to fiscal pressure, patient
payments increased substantially,
resulting in weakened financial
protection. Thus, in the subsequent
years, some fee reduction took
place [45].








Cost Sharing for Outpatient
Medicines








(except for visits to
specialists without
referrals) [46,47]
Patients pay the full price for




individuals), for which full or
partial reimbursement is applied
(list B of medicines), or suffer
from certain diseases, e.g.,
tuberculosis, cancers,
schizophrenia, metabolic
diseases, or asthma, for which
medicines are now fully
reimbursed (list A of medicines).
Everyone pays the costs above
the reference price [26,47,56].
None
The majority of population pay
the full price for medical
products and dental care [46,47].
A 50% reimbursement rate for
medicines on list B for
pensioners, partially disabled
and recipients of social benefits.
Full reimbursement is available
for children, the severely
disabled, people with specific
conditions, and since 2020, for
low-income older adults
[26,47,56].
Providers might charge patients the
difference between the price and the
actual cost of a treatment if patients opt
for a treatment that is more expensive.
There are concerns regarding the poor
regulation and lack of transparency in
these charges [46,47].
Since 2017, there have been significant
changes in the reimbursement policy
aimed at decreasing out-of-pocket
payments for medicines. Before April
2019, there was percentage co-payment
(50%, 20%, or 10%) for medicines on a
disease-specific list (list A) [26].
Poland None [48,49].
Fixed co-payment of PLN 3.20
(€0.7) or percentage co-payments
of 30% or 50%, and any cost
above the reference price [48,56].
For medical products: payments
on top of the reimbursement




No cost sharing for dental care.
The majority of the population
pay the full price for dental
care [48,49].
Exemptions apply to only a few
groups, i.e., veterans, organ or
blood donors, people aged 75+
(since 2016, for a broad range of
medicines), pregnant women
(since 2020, for certain medicines)
children (only for some medical
products) [48,49].
Until 2010, extra billing in dental care
was allowed, i.e., patients had had the
possibility of opting for more
expensive materials within the
publicly financed system and pay any
extra cost [49].








Cost Sharing for Outpatient
Medicines








rates (0–100%) Many medicines
(1/3) provided free of charge.
Flat fee for prescription
€0.17 [50,56].
Different percentage co-insurance
rates for medical products.
Cost sharing for some dental
services [50].
Maximum limits for co-payments
for prescribed medicines. A wide
range of medical devices with
individually reduced cost
sharing [50].




per day), and emergency care visits
(approximately €2) were in place. In
2006, co-payments for outpatient and
inpatient care were abolished, while
other co-payments were reduced. Yet,
providers continued to collect
payments for health and health-related
services. In 2015, a regulation was




from 10% to 90% depending
on the type of services [52].
Percentage co-payments (max.
30% for medicines on the positive
list and min. 75% for medicines
on the intermediate list) [52].
Percentage co-payments for
dental care and medical products




and chronically ill people [52,60].
Cost sharing was introduced in 1992
along with the compulsory health
insurance system [14]. A vast majority
of the population has private
complementary insurance to cover
cost-sharing obligations [52,60]. The
economic crisis of 2008 led to an
increase in co-payments [29].
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The countries included in the study rely strongly on cost sharing for medicines. In all
countries, with the exemption of Czechia, patients need to pay for prescribed outpatient
medicines in some form of percentage co-payment. A system of reference pricing is also in
place, and patients additionally pay the cost above the reference price. In addition, medical
products and dental care for adults, if included in the benefit package, are subject to heavy
patient payments in all of the analyzed countries.
In all countries, cost sharing is accompanied by protection mechanisms, such as
exemptions for vulnerable population groups or limits on payments. Yet, the extent of
protection policy varies, and in some countries the mechanisms are considered weak (e.g.,
Latvia, Hungary, Poland). They do not always protect low-income individuals, or there
is no overall cap on payments to relieve the financial burden for frequent users. In one
country, i.e., Slovenia, patients are protected against payments by complementary private
insurance that covers cost-sharing obligations.
4. Discussion
This paper presents the results of quantitative and qualitative data analysis on health-
care financing in eight CEE countries: Czechia, Estonia, Hungary, Latvia, Lithuania, Poland,
Slovakia, and Slovenia. Based on available data, we have analyzed the changes in the level
and structure of health spending over the last nearly two decades and the gaps in universal
health coverage in these countries. The previous research on the topic has presented either
a comparative perspective on health spending and universal health coverage e.g., [65–67]
using quantitative data, or a specific aspect of healthcare financing (e.g., medicine reim-
bursement, e.g., [56,62], or patient cost sharing, e.g., [14,64]) or focused on individual
countries (e.g., [49,63]). This study adds to the available literature by presenting a cross-
country comprehensive analysis of healthcare financing and coverage using quantitative
and qualitative data. Despite this strength of our study, the presented results should be
interpreted, bearing in mind its limitations. As we have applied a desk research method, we
might not have the most accurate and latest information on each of the analyzed countries.
To some extent, we have mitigated this limitation by cross-checking data from different
sources. The comparability of presented data (including quantitative data on healthcare
expenditure) across the countries and over time is also limited, though we endeavored to
use analogous sources of data for each country.
Our results show that in seven out of eight analyzed countries, the level of resources
devoted to health in relation to country GDP has increased since 2000, and there was a
statistically significant upward trend over time in most of the countries. Nevertheless, the
rates can still be considered low when compared to the EU-27 average (8.3% in 2018) [54],
placing the EU-8 countries among the lowest spenders in the EU. Thus, the distance
between west and east, which reflects the diverse economic and political evolution of these
two parts of Europe since the end of World War II [8,9], remains significant when it comes
to healthcare expenditure.
The results also indicate that the EU-8 countries increase priority given to health when
making decision concerning public spending. In the majority of the analyzed countries, the
share of health spending in total government expenditure has risen since 2000, though a
significant trend was evident only in a few countries, and the increase was rather small,
allowing only Czechia to reach a level above the EU average [54]. Despite this positive
change, government resources have not been sufficient to significantly improve healthcare
financing structure, and overall, the contribution of public resources in healthcare financing
in the EU-8 countries has shown a downward trend. This is due to reducing the government
responsibility for healthcare financing in countries where, at the start (2000), healthcare
funds came largely from public sources (Czechia, Estonia, Slovakia), and rather small or no
progress in lowering out-of-pocket spending in other countries, where their level is still
above the EU average of 22% [54].
The results of qualitative data analysis indicate that the EU-8 countries aimed to
ensure universal population coverage of their public health systems, though in most of the
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EU-8 countries, a small fraction of the population remain uninsured. In fact, the numbers
of uninsured individuals might be lower than indicated in the statistics, as some of the
registered uninsured are living and working abroad and thus, are most likely covered by
the systems in their countries of residence. Nevertheless, there is still a need to improve
the transparency and flexibility of the systems to ensure stable coverage for all eligible
individuals, including those in nonstandard employment. It is also worth noting that in
the countries with a health insurance system, the entitlement to healthcare services for a
significant part of the population (those who are economically inactive) is not conditional
on paying insurance contributions. Hence, the insurance systems in these countries rely
strongly on taxes to pay for noncontributing individuals. When the state does not take
on the responsibility of contributing for the nonactive population (Estonia, Poland) or the
contribution paid on their behalf is significantly lower than for the economically active
population, the sustainability of healthcare financing might be at risk.
Our results also indicate that the low public health spending and the tension between
needs and available resources have led to significant gaps in service and cost coverage as a
result of the explicit decision to shift the cost of care to households, or implicit rationing.
Explicit mechanisms, such as excluding services and goods from the benefit package or
introducing patient cost sharing, are commonly applied for medical products, dental care,
and medicines. In the case of medicines, a transparent and systematic approach is often
used as the list of covered pharmaceuticals is regularly updated based on HTA criteria.
Nevertheless, such open decisions to reduce government responsibility for financing
healthcare are politically challenging and might trigger public opposition. For these
reasons explicit mechanisms are not always successfully applied in CEE countries when it
comes to basic healthcare services (primary care, inpatient and outpatient specialist care).
As our review shows, obligatory patient cost sharing for healthcare services is present
in three countries (Estonia, Latvia, and Slovenia), while three other countries (Czechia,
Hungary, and Slovakia) implemented and later withdrew patient payments due to public
opposition. Previous evidence showed that public disapproval of obligatory payments for
publicly financed healthcare services in CEE countries is mainly driven by dissatisfaction
with quality and access to care, and the failure of the cost-sharing system to remedy this
situation for patients [68].
Implicit measures that are not directly aimed at increasing out-of-pocket payments but
might ultimately lead to patients paying for care, such as waiting times or volume limits
imposed by public payers on healthcare providers, might be responsible for a significant
part of out-of-pocket payments in the analyzed countries. This was confirmed by the
relatively high share of out-of-pocket payments in financing outpatient specialist services
observed in countries with comprehensive service and cost coverage (Hungary, Poland,
and Lithuania). Long waiting times and poor quality of services might be the reasons
for using privately financed healthcare services, purchasing over-the-counter medicines
(commonly used in CEE countries as shown in the European Health Interview Survey [69],
or even paying informally for care. The prevalence of informal patient payments has
decreased over years in the CEE region, though they still constitute a barrier to access
and a financial burden for households in many countries [63,70,71]. The 2017 Special
Eurobarometer report on corruption, indicated that among the eight countries, informal
patient payments (in cash or in kind) were most widespread in Hungary (reported by 17%
of those who had used healthcare in the previous 12 months), while Slovenia and Estonia
occupied the opposite end with 3% of users paying informally [72].
Another factor, apart from the availability of financial resources, that has been rec-
ognized as an important reason for limited access to health services and lengthening the
average waiting time in CEE countries is the shortage of healthcare professionals [73–75].
The number of practicing doctors and nurses per 1000 population among EU-8 countries is
significantly lower than the EU average. Moreover, between 2000 and 2018, the number of
practicing doctors per capita increased in the vast majority of EU countries, while in the
analyzed EU-8 countries this increase was marginal (especially slight changes were noticed
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in Poland, Latvia, Estonia, Hungary, and Slovakia) [54]. Research has also indicated that
free health professional mobility disproportionally benefits richer countries from the “old”
EU at the expense of less advantaged countries (including the EU-8 countries), which are
not able to draw foreign-trained medical staff or retain their national health workforce [75].
Despite some common features of CEE countries, our results show a great diversity
across the eight countries analyzed in this paper. This heterogeneity was observed during
the transition period and has continued until recent years as a result of persisting economic,
social, or political differences across the countries, which are indicated in Table 1 [8].
The greatest challenges are in Latvia, where low public resources spent on health do
not allow for a broad scoped benefit package to be made available free of charge for patients.
Hence, cost sharing is commonly applied and out-of-pocket payments are responsible for
nearly 40% of current health expenditure in Latvia. The financial hardship for households
is significant, with 13% of households experiencing catastrophic out-of-pocket payments,
as shown by a recent WHO study [40]. Moreover, when compared to other European
countries, Latvia is characterized by a high proportion of the population with unmet needs
for medical examination or treatment (due to costs, distance, or waiting times), i.e., 6.2% in
2018, based on the EU-Statistics on Income and Living Conditions (EU-SILC) [76]. All this
motivated the implementation of healthcare funding reform, which resulted in a shift from
a tax-based to an insurance-based model. Nevertheless, the potential of such a change to
solve Latvia’s health system problems has been disputed [45,77,78], and the reform has
been recently cancelled in the fear of deepening inequalities in access to healthcare services.
Countries that stood out positively in our analysis were Czechia and Slovenia. Both
countries are characterized by the highest spending on healthcare. Moreover, out-of-pocket
payments in these countries constitute a relatively low share of healthcare expenditure,
i.e., below 15%. In Czechia, this result was achieved through a high priority given to
health and significant (though diminishing over the years) government involvement in
covering healthcare costs (little use of cost sharing for publicly financed healthcare and
broad coverage of services). In Slovenia, the government’s role in financing healthcare
is smaller and patient cost sharing is commonly applied. However, voluntary private
insurance, which is commonly purchased by Slovenians, is taking over the cost-sharing
obligations, leaving households with no need to pay out-of-pocket.
The examples of Czechia and Slovenia present different ways of ensuring universal
health coverage. On the one hand, by prioritizing budget and mobilizing more public
resources for health, and on the other hand, by creating conditions for private insurance
to take a more significant role in financing healthcare. The former measure is challenging
in less wealthy countries where competition for scarce resources is greater, and calls for
a strong political will. The latter however requires government capacity to control for
and mitigate against the adverse effects of private insurance, such as risk selection or the
inability of poor individuals and those with worse health status to purchase insurance. For
this reason, it is not a commonly used option in European countries [79].
5. Conclusions
In the last two decades, the EU-8 countries have made moderate progress in achieving
universal health coverage, with a still high reliance on out-of-pocket expenditure in many
countries. The health and economic crisis caused by the recent COVID-19 pandemic will
likely hinder countries’ efforts toward universal health coverage through, on the one hand,
increasing health needs, and on the other hand, reducing public revenues and increasing
people’s economic vulnerability.
This calls for a careful budget prioritization to secure additional healthcare resources
to maintain a provision of essential healthcare services and protect households against
financial catastrophe and impoverishment. This is also a time when new sources of
revenues (external loans, grants) might play a more important role in financing healthcare.
A revision of healthcare coverage might also be required, e.g., extending population
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coverage to ensure access to necessary healthcare services in order to control the pandemic,
or reducing cost-sharing obligations for those most affected by the economic crisis.
Our results indicate that there is room for improving universal health coverage in
CEE countries, extending the coverage to include all economically inactive groups, and
improving the flexibility of the insurance system so that the continuity of insurance is
maintained during labor market transitions. A systematic and evidence-based approach
to establish a benefit basket and patient cost-sharing obligations might help to ensure
more equal access to essential and efficient healthcare services. There is also a need for
improving protection against cost-sharing obligations, particularly for those with a low
ability to pay (through exemptions) and populations with higher needs (through caps on
payments). Since gaps in the quality of care play an important role in burdening patients
with out-of-pocket payments, they also call for greater policy attention.
This research does not remain without limitations, which are outlined in the discussion
section. Yet, our results can serve as a base for further research on healthcare expenditure
and health coverage in CEE countries. It is particularly relevant to study universal health
coverage achievements, e.g., financial protection against catastrophic and impoverishing
out-of-pocket payments, equity in access to healthcare, and quality of care. Studies on
the effectiveness of policies and programs implemented in CEE countries to improve
universal health coverage could also facilitate evidence-based policymaking. Finally, a more
sophisticated analysis could be applied to study trends in healthcare expenditure, covering
various determinants of healthcare expenditure, including demographic, economic, social,
and health system factors.
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